NCT07659639 Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
| NCT ID | NCT07659639 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Policlinico Universitario Campus Bio-Medico |
| Condition | Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2029-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-09-01 with a primary completion date of 2029-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.
Eligibility Criteria
\*\*Inclusion criteria for patients with PDAC and IPMN:\*\* * No history of prior neoplastic diseases; * Adequate renal and hepatic function; * No hematologic disorders; * Age ≥ 18 years; * No active infections; * Written informed consent. \*\*Exclusion criteria:\*\* * Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health; * Ongoing therapies that could interfere with the study or alter the results.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07659639 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07659639 currently recruiting?
Yes, NCT07659639 is actively recruiting participants. Contact the research team at d.caputo@policlinicocampus.it for enrollment information.
Where is the NCT07659639 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT07659639 clinical trial?
NCT07659639 is sponsored by Fondazione Policlinico Universitario Campus Bio-Medico. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.